Key Highlights
•
A new study identified a specific signaling pathway, SEMA3C/PLXND1, that controls collagen production in keloid scars via the TGF-β1 pathway. This discovery provides a potential new target for treatments to reduce the excessive scarring seen in keloids, which are difficult to manage.
Source →
•
Five-year follow-up data from a clinical trial shows that a personalized mRNA cancer vaccine, when combined with immunotherapy, continues to cut the risk of melanoma returning or death by about 49%. This long-term benefit strengthens the case for using custom-made vaccines as a powerful tool in the fight against skin cancer.
Source →
•
Researchers have found that small RNA molecules derived from tRNAs are expressed differently in babies with necrotizing enterocolitis, a serious intestinal disease. Identifying these molecules could lead to new biomarkers for early detection of this life-threatening condition in newborns.
Source →
•
A study of patients with cardiac amyloidosis, a condition where protein builds up in the heart, found that nearly 40% did not have preserved heart function, challenging the common assumption. Combining measurements of heart squeeze, strain, and blood flow created a better model for predicting patient outcomes than any single test alone.
Source →
•
A phase 3 trial showed that an oral form of the chemotherapy drug paclitaxel was comparable to the standard intravenous version for treating certain advanced breast cancers. An effective oral option could make treatment more convenient for patients by eliminating the need for lengthy IV infusions in a clinic.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
